PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
23722461-5	2013	RESULTS: Thalidomide (20 muM) not only inhibited cell proliferation after 24 h [fold increase of cell number, 0.85 +- 0.09 vs. 1.47 +- 0.14 (treatment vs. control group); P < 0.01] and 48 h of incubation (0.85 +- 0.10 vs. 1.97 +- 0.12; P < 0.001), it also inhibited cell migration and slowed wound closure at 24 h (P < 0.001).	Thalidomide	9-20	latexin	Homo sapiens	25-28	
26231201-6	2015	Treatment of human myeloma cell lines such as MM1.S, OPM2, and U266 with thalidomide (100 muM) and its structural analog lenalidomide (10 muM) results in stabilization of CRBN and elevation of CRBN protein levels.	Thalidomide	73-84	latexin	Homo sapiens	90-93	
26231201-6	2015	Treatment of human myeloma cell lines such as MM1.S, OPM2, and U266 with thalidomide (100 muM) and its structural analog lenalidomide (10 muM) results in stabilization of CRBN and elevation of CRBN protein levels.	Thalidomide	73-84	latexin	Homo sapiens	138-141